53890-39-4

Basic information

• Product Name: 6-CHLORO[1,2,4]TRIAZOLO[4,3-B]PYRIDAZIN-3-AMINE
• Synonyms: 1,2,4-Triazolo[4,3-b]pyridazin-3-amine, 6-chloro-
• CAS NO: 53890-39-4
• Molecular Formula: C₅H₄ClN₅
• Molecular Weight: 169.57
• Mol File: 53890-39-4.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 6-CHLORO[1,2,4]TRIAZOLO[4,3-B]PYRIDAZIN-3-AMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-CHLORO[1,2,4]TRIAZOLO[4,3-B]PYRIDAZIN-3-AMINE(53890-39-4)
• EPA Substance Registry System: 6-CHLORO[1,2,4]TRIAZOLO[4,3-B]PYRIDAZIN-3-AMINE(53890-39-4)

Safety Data

• Hazardous Substances Data: 53890-39-4(Hazardous Substances Data)

Upstream product

• 17284-97-8 3-Chloro-6-hydrazinopyridazine 
• 506-68-3 bromocyane 
• 1178583-12-4 6-chloro-[1,2,4]triazolo[4,3-b]pyridazin-3-ylamine hydrobromide 

Downstream Products

• 1178578-27-2 2-(6-chloro-3-imino-[1,2,4]triazolo[4,3-b]pyridazin-2-yl)-1-(3,5-di-tert-butyl-4-hydroxyphenyl)ethanone trifluoroacetate 
• 1178578-25-0 N-[3-[2-(6-ethoxy-3-imino-[1,2,4]triazolo[4,3-b]pyridazin-2-yl)acetyl]-5-(pentafluorosulfanyl)phenyl]acetamide trifluoroacetate 
• 1180517-32-1 1-{2-[3-acetylamino-5-(pentafluorosulfanyl)phenyl]-2-oxoethyl}-3-amino-6-ethoxy-[1,2,4]triazolo[4,3-b]pyridazin-1-ium trifluoroacetate 
• 1166817-01-1 C₁₇H₁₇F₃N₆ 

Relevant articles and documents

Towards discovery of novel scaffold with potent antiangiogenic activity; design, synthesis of pyridazine based compounds, impact of hinge interaction, and accessibility of their bioactive conformation on VEGFR-2 activities

Pyridazine scaffolds are considered privileged structures pertaining to its novelty, chemical stability, and synthetic feasibility. In our quest towards the development of novel scaffolds for effective vascular endothelial growth 2 (VEGFR-2) inhibition with antiangiogenic activity, four novel series of pyridazines were designed and synthesised. Five of the synthesised compounds; namely (8c, 8f, 15, 18b, and 18c) exhibited potent VEGFR-2 inhibitory potency (>80%); with IC50 values ranging from low micromolar to nanomolar range; namely compounds 8c, 8f, 15, 18c with (1.8 μM, 1.3 μM, 1.4 μM, 107 nM), respectively. Moreover, 3-[4-{(6-oxo-1,6-dihydropyridazin-3-yl)oxy}phenyl]urea derivative (18b) exhibited nanomolar potency towards VEGFR-2 (60.7 nM). In cellular assay, the above compounds showed excellent inhibition of VEGF-stimulated proliferation of human umbilical vein endothelial cells at 10 μM concentration. Finally, an extensive molecular simulation study was performed to investigate the probable interaction with VEGFR-2.

TRIAZOLIUM SALTS AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS

The invention relates to novel compounds of formula I where X, A?, Q1, Q2 Q3, R2, R3, R4, R5, R6, R7, R8 and R9 are each as defined below. The compounds of formula I have antithrombotic activity and inhibit especially protease-activated recepto

TRIAZOLOPYRIDAZINES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS

The invention relates to novel compounds of formula I where R1, R2, R3, R4, R5, R6, R7, R8, Q1, Q2 and Q3 are each as defined below. The compounds of formula I have antithrombotic activity and inhibit especially protease-activated receptor 1 (PAR1). The i

Substituted triazolopyridazines, pharmaceutical compositions and use

This invention is directed to a group of compounds which are acyl derivatives of amino substituted triazolopyridazines. They are prepared by the reaction of an aminotriazolopyridazine or an aminotriazolophthalazine with an appropriate acid chloride. These compounds possess bronchodilating and antiallergenic activity.